bioavailability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
=== Dosage === Adult: Each tablet contains flupentixol 0.5 mg and melitracen 10 mg. The usual adult dose is one tablet in the morning and one at midday; in severe cases the morning dose may be increased to two tablets. The maximum recommended dose is four tablets per day. Elderly: The usual starting dose is one tablet in the morning; in severe cases, one tablet may also be given at midday.
==== Permanent ==== Low-velocity items, such as knives and swords, are usually propelled by a person's hand, and usually do damage only to the area that is directly contacted by the object. The space left by tissue that is destroyed by the penetrating object as it passes through forms a cavity; this is called permanent cavitation.
== Detection in humans == Two principal techniques have been used most often to detect levels of aflatoxin in humans, though they are not commercially available. The first method is measuring the AFB1-guanine adduct in the urine of subjects. The presence of this breakdown product indicates exposure to aflatoxin B1 during the past 24 hours. This technique measures only recent exposure, however. Due to the half-life of this metabolite, the level of AFB1-guanine measured may vary from day to day, based on diet, and it is not ideal for assessing long-term exposure. Another technique that has been used is a measurement of the AFB1-albumin adduct level in the blood serum. This approach provides a more integrated measure of exposure over several weeks or months.
Sources: en.wikipedia.org
In blood serum, the content of nitrogenous substances such as urea and creatinine (uremia or azotemia) and phosphate (hyperphosphatemia). The increased phosphate concentration is the result of the reduced glomerular filtration rate. Among other things, fibroblast growth factor 23 (FGF-23) is involved here, which is more sensitive than the phosphate level in the event of an incipient disorder. The potassium content is usually reduced (hypokalemia), but can also be increased—the reverse is true for the sodium content. If the cause of the kidney disease lies in the renal corpuscles, albumin deficiency (hypalbuminemia) and excess cholesterol (hypercholesterolemia) also occur. The determination of cystatin C is not evaluated for cats, this protein can also be elevated in cats with hyperthyroidism or with glucocorticoids and drop sharply for several hours after food intake. Recent studies suggest that symmetric dimethylarginine (SDMA) is a suitable marker for renal function in cats. The SDMA concentration in serum shows close correlations with the glomerular filtration rate and the creatinine concentration. It can already detect a 40% loss of kidney function, i.e. before there is an increase in creatinine in the blood. The most sensitive method of kidney function diagnostics is the direct determination of the glomerular filtration rate via the clearance, which is already reduced in chronic kidney disease before azotemia occurs. Various substances have been evaluated for cats, the most practical being creatinine and iohexol.
Vopratelimab (JTX-4014) by Jounce Therapeutics As of 2020 entered Phase I trial Spartalizumab (PDR001) is a PD-1 inhibitor developed by Novartis to treat both solid tumors and lymphomas, which as of 2018 has entered Phase III trials. Camrelizumab (SHR1210) is an anti-PD-1 monoclonal antibody introduced by Jiangsu HengRui Medicine Co., Ltd. that recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent Biologics and Eli Lilly for patients with non-small cell lung cancer (NSCLC). INCMGA00012 (MGA012) is a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics. AMP-224 by AstraZeneca/MedImmune and GlaxoSmithKline AMP-514 (MEDI0680) by AstraZeneca Acrixolimab (YBL-006) by Y-Biologics Sasanlimab by Pfizer
At some point in his reign a widespread uprising occurred, a large coalition of city-states led by Iphur-Kis of Kish (Sumer) and Amar-Girid of Uruk, joined by Enlil-nizu of Nippur, and including the city-states of "Kutha, TiWA, Sippar, Kazallu, Kiritab, [Api]ak and GN" as well as "Amorite [hi]ghlanders". The rebellion was joined by the city of Borsippa, among others. We know of these events from a number of Old Babylonian copies of earlier inscriptions as well as one contemporary record from the Old Akkadian period. The Bassetki Statue, discovered in 1974, was the base of a life-sized copper statue of Naram-Sin. It reads:
Major football clubs in West Yorkshire include Leeds United, Huddersfield Town, and Bradford City. Rugby league is also big in West Yorkshire. The teams who are, or have been, in the Super League are Bradford Bulls, Castleford Tigers, Halifax Panthers, Huddersfield Giants, Leeds Rhinos, and Wakefield Trinity. Other rugby league clubs in West Yorkshire include Batley Bulldogs, Dewsbury Rams, Featherstone Rovers, Hunslet Hawks and Keighley Cougars. Any combination of these teams playing against each other would be called a West Yorkshire derby even if the rivalry is not as great as other rivalries between teams in the area. The main rugby union club in the county is Yorkshire Carnegie. Elland Road is the largest stadium in the area, hosting Leeds United. The Headingley Stadium, a stadium complex also in Leeds, consists of a cricket and a rugby ground. The cricket ground is home of the Yorkshire County Cricket Club and the rugby ground is home to Leeds Rhinos. In Huddersfield, the John Smith's Stadium is home to Huddersfield Town and Huddersfield Giants. In Bradford, Valley Parade is the home of Bradford City, whereas the Odsal Stadium is the home of the Bradford Bulls. Other stadiums include Wheldon Road (Castleford), The Shay (Halifax), Belle Vue (Wakefield), Mount Pleasant (Batley), Crown Flatt (Dewsbury), Post Office Road (Featherstone), John Charles Centre for Sport (Hunslet) and Cougar Park (Keighley). There are two racecourses in West Yorkshire: Pontefract and Wetherby.
Sources: en.wikipedia.org
Furthermore, specific LTBP isoforms have a propensity to associate with specific LAP•TGF-β isoforms. For example, LTBP-4 is reported to bind only to TGF-β1, thus, mutation in LTBP-4 can lead to TGF-β associated complications which are specific to tissues that predominantly involves TGF-β1. Moreover, the structural differences within the LAP's provide different latent TGF-β complexes which are selective but to specific stimuli generated by specific activators.
== Origins of pathology == Early understanding of the origins of diseases constitutes the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. The Greek physician Hippocrates, the founder of scientific medicine, was the first to deal with the anatomy and the pathology of human spine. Galen developed an interest in anatomy from his studies of Herophilus and Erasistratus. The concept of studying disease through the methodical dissection and examination of diseased bodies, organs, and tissues may seem obvious today, but there are few if any recorded examples of true autopsies performed prior to the second millennium. Though the pathology of contagion was understood by Muslim physicians since the time of Avicenna (980–1037) who described it in The Canon of Medicine (c. 1020), the first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161) who proved that the skin disease scabies was caused by a parasite, followed by Ibn al-Nafis (b. 1213) who used dissection to discover pulmonary circulation in 1242. In the 15th century, anatomic dissection was repeatedly used by the Italian physician Antonio Benivieni (1443–1502) to determine cause of death. Antonio Benivieni is also credited with having introduced necropsy to the medical field. Perhaps the most famous early gross pathologist was Giovanni Morgagni (1682–1771).
Ovaleap was approved for medical use in the European Union in September 2013. It was approved for medical use in Australia in March 2021. Bemfola was approved for medical use in the European Union in March 2014.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.